2. Search Result
Search Result
Results for "

viral fusion

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

6

Inhibitory Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W127378
    DOTAP methylsulfate
    10+ Cited Publications

    1,2-Dioleoyl-3-trimethylammonium-propane methylsulfate

    		 Liposome Others
    DOTAP methylsulfat is a cationic lipid reagent, a cationic derivative of trimethylammonium, linked to two 18-carbon fatty acid tails, each with a single olefin group. DOTAP methylsulfat can self-assemble with negatively charged ions (such as DNA) to form complexes, which can be adsorbed to the cell membrane surface and enter the cell by electrostatic interaction and endocytosis, respectively. DOTAP methylsulfat promotes endosomal membrane fusion with its own hydrophobic domain, releases DNA into the cytoplasm, and exerts gene delivery function. DOTAP methylsulfat can be widely used in research fields such as gene therapy, cell transfection, and non-viral vector design .
    DOTAP methylsulfate
  • HY-U00434
    3BDO
    Maximum Cited Publications
    21 Publications Verification

    		 mTOR Autophagy Apoptosis Infection Inflammation/Immunology
    3BDO is a IFITM3 modulator and mTOR activator with antiviral and autophagy-inhibiting effects. 3BDO exhibits inhibitory activity against porcine coronaviruses. 3BDO increases the protein abundance of IFITM3, inhibits virus-cell membrane fusion, and blocks viral entry. 3BDO inhibits the entry of transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and porcine respiratory coronavirus into host cells. 3BDO can be used for research on porcine coronavirus infection .
    3BDO
  • HY-P99853
    Diridavumab

    CR6261

    		 Influenza Virus Infection
    Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
    Diridavumab
  • HY-P11460
    Vectofusin-1

    		Drug Derivative Infection
    Vectofusin-1 is a histidine-rich cationic amphipathic peptide derived from the LAH4 (HY-P0311) peptide family, and also acts as a Viral entry enhancer. Vectofusin-1 promotes the adhesion and fusion of retroviral/lentiviral vectors with cell membranes during viral entry, thereby improving transduction efficiency. Vectofusin-1 potently enhances lentiviral transduction of cells .
    Vectofusin-1
  • HY-P0328
    VSV-G tag Peptide
    1 Publications Verification

    		 VSV Infection
    VSV-G tag Peptide is a 11 amino acid peptide derived from the Vesicular Stomatitis viral glycoprotein. VSV-G tag Peptide can integrate into the cell membranes of animal cells, induce cell fusion, and significantly enhance the efficiency of DNA transfection into animal cells. VSV-G tag Peptide can be used for research on drug delivery .
    VSV-G tag Peptide
  • HY-P991059
    VIS-410

    		Influenza Virus Infection
    VIS-410 is an antibody inhibitor targeting the stem region of hemagglutinin (HA). VIS-410 inhibits influenza virus replication by blocking HA-mediated membrane fusion. VIS-410 exhibits broad-spectrum neutralization against influenza A viruses with group 1 and group 2 hemagglutinins, including subtypes such as H1N1, H3N2, H5N1, and H7N9 (H5N1 IC50 = 1.5 μg/mL). VIS-410 is applicable to research related to influenza A virus infection .
    VIS-410
  • HY-120632
    BMS-433771

    		RSV Infection
    BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease .
    BMS-433771
  • HY-178137
    SCR007

    		SARS-CoV Hepatitis E Virus (HEV) Filovirus Infection
    SCR007 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR007 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR007 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR007 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR007 can be used for the study and prevention of enveloped virus pandemics .
    SCR007
  • HY-19874
    RFI-641

    		RSV Infection
    RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), with an IC50 of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .
    RFI-641
  • HY-114437
    Fusion Inhibitory Peptide

    Z-D-Phe-Phe-Gly-OH; FIP; Virus Replication Inhibitory Peptide

    		 Influenza Virus Infection
    Fusion Inhibitory Peptide (Z-D-Phe-Phe-Gly-OH, FIP, Virus Replication Inhibitory Peptide) is a potent inhibitor of the virus replication, by inhibiting the membrane fusing activity of a viral glycoprotein .
    Fusion Inhibitory Peptide
  • HY-178135
    SCR005

    		SARS-CoV Filovirus Hepatitis E Virus (HEV) Infection
    SCR005 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR005 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR005 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR005 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR005 can be used for the study and prevention of enveloped virus pandemics .
    SCR005
  • HY-161804
    GNF-2-deg

    		PROTACs Dengue Virus Infection
    GNF-2-deg is a PROTAC degrader for dengue virus envelope protein (DENV E protein) with DC50 of 0.83 μM. GNF-2-deg prevents viral entry by inhibiting E-mediated membrane fusion, prevents virion production by protein degradation, and thereby exhibits antiviral activity against DENV 2 with EC90 of 3.5 μM. GNF-2-deg exhibits antiviral activity against ZIKV, JEV, WNV and YFV with EC90 of 1.96-7.79 μM. (Pink: ligand for target protein (HY-161805); Black: linker (HY-42149); Blue: ligand for E3 ligase (HY-23095))
    GNF-2-deg
  • HY-P11037
    soVIRIP

    		HIV Infection
    soVIRIP is a virus inhibitory peptide with an IC50 of 1.2  μM for HIV-1 . soVIRIP binds to the HIV-1 GP41 fusion peptide and inhibits viral fusion and entry into host cells. soVIRIP has broad-spectrum anti-HIV-1 activities with nontoxicity in zebrafish models. soVIRIP can used for viral infections research .
    soVIRIP
  • HY-122204
    5M038

    		HIV Infection
    5M038 is an inhibitor of HIV envelope-mediated fusion with potent inhibitory activity against gp41-mediated membrane fusion. 5M038 prevents the formation of the gp41 post-fusion conformation and inhibits envelope-mediated membrane fusion in cell-cell fusion and viral infectivity assays. 5M038 has shown broad fusion inhibition in tests against multiple HIV-1 subtypes, including M and T strains. 5M038 targets a highly conserved hydrophobic pocket and binds to the gp41 trimer, thereby exerting its inhibitory effect .
    5M038
  • HY-160880
    EBOV-IN-5

    		Filovirus Infection
    EBOV-IN-5 (compound 14) is an antiviral agent that inhibits Ebola virus (EBOV) infection. EBOV-IN-5 inhibits the binding of the EBOV glycoprotein EBOV-GPcl to NPC1, an indispensable host receptor required for viral fusion/entry .
    EBOV-IN-5
  • HY-103300
    NPE-caged-proton

    		Endogenous Metabolite Infection
    NPE-caged-proton is a reagent that releases protons under UV light and has the activity of activating the fusion protein GP64 under weak acidic conditions. NPE-caged-proton can promote the binding of enveloped viruses to liposome membranes with acidic phospholipids in an environment of pH 4.0 to 5.5, thereby initiating membrane fusion. The ultraviolet unblocking effect of NPE-caged-proton can lower the environmental pH, thereby triggering the process of viral membrane fusion. When studying the interaction between viruses and cell membranes, NPE-caged-proton provides a valuable tool for revealing the subtle behaviors of viruses in different chemical and biochemical environments .
    NPE-caged-proton
  • HY-107009
    CTC 96

    		VZV HSV VSV Infection
    CTC 96 is an antiviral agent, showing inhibitory effects particularly on herpes viruses and adenoviruses. CTC 96 directly blocks the fusion process between the viral envelope and the cell membrane, preventing the entry of viral nucleic acids and proteins into the cells. CTC 96 can completely block the penetration and intercellular transmission of HSV-1, preventing the synthesis of viral proteins and mRNA. CTC 96 exhibits significant anti-adenovirus activity in rabbit eye models. CTC 96 is also effective against varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV). CTC 96 can be used for broad-spectrum antiviral research .
    CTC 96
  • HY-P10308
    [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92)

    		HIV Infection
    [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) is a selective inhibitor of HIV-1. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) inhibits viral infection and cell fusion by blocking the interaction between HIV-1 and CD4 molecules. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) can completely inhibit fusion formation at a concentration of 25 μM .
    [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92)
  • HY-120632A
    BMS-433771 dihydrochloride hydrate

    		RSV Infection
    BMS-433771 dihydrochloride hydrate is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 dihydrochloride hydrate is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 dihydrochloride hydrate can be used for the research of respiratory tract disease .
    BMS-433771 dihydrochloride hydrate
  • HY-182030
    RSV fusion protein IN-1

    		RSV Infection
    RSV fusion protein IN-1 is an orally active RSV pre-fusion F protein inhibitor with an IC50 of 0.10 nM against RSV. RSV fusion protein IN-1 forms stable hydrogen bonds and π-π stacking interactions with pre-fusion F protein to block viral fusion and entry. RSV fusion protein IN-1 suppresses RSV F protein expression in epithelial cells. RSV fusion protein IN-1 reduces viral burden in the lungs of RSV-infected murine models.RSV fusion protein IN-1 can be used for the research of respiratory syncytial virus (RSV) infection .
    RSV fusion protein IN-1
  • HY-182913
    SARS-CoV-2-IN-122

    		SARS-CoV Infection
    SARS-CoV-2-IN-122 is a SARS-CoV-2 inhibitor by targeting the S2 subunit of the spike protein. SARS-CoV-2-IN-122 interacts with residues linked to membrane fusion-associated conformational rearrangements, interfering with viral entry events. SARS-CoV-2-IN-122 inhibits SARS-CoV-2 replication, lacks direct virucidal activity, and does not impair viral-host cell attachment. SARS-CoV-2-IN-122 exhibits activity against SARS-CoV-2 variants including B.1 and Omicron (BA.2.86.1). SARS-CoV-2-IN-122 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2-IN-122
  • HY-W1135843
    ARN-75039

    		Arenavirus Infection
    ARN-75039 is an orally active arenavirus inhibitor. ARN-75039 binds to sites on the GP2 subunit of the mammarenavirus glycoprotein complex, stabilizes prefusion conformation, and blocks viral entry and endosomal membrane fusion to inhibit viral replication and spread. ARN-75039 can be used for the research of lassa fever, arenaviral hemorrhagic fever, and lethal Junín virus infection .
    ARN-75039
  • HY-183592
    Anti-virus agent 2

    		Orthopoxvirus Drug Derivative Infection
    Anti-virus agent 2 is an orally active and selective anti-orthopoxvirus (poxvirus) agent, with EC50 values of 6.1 μM and 47.1 μM against VTT-Fluc and MPXV clade IIb, respectively. Anti-virus agent 2 covalently binds to viral A17L protein and mRNA methyltransferase, blocks viral membrane fusion and intracellular biosynthesis, and acts on multiple stages of the viral replication cycle. Anti-virus agent 2 achieves viral inhibition in nude mouse models. Anti-virus agent 2 can be used for the research of orthopoxvirus infections such as monkeypox and smallpox .
    Anti-virus agent 2
  • HY-P992175
    ADI-14448

    		RSV Infection
    ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a Kd of 3.8 × 10 -10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection .
    ADI-14448
  • HY-180145
    Furin-IN-3

    		Furin Influenza Virus Infection
    Furin-IN-3 (Compound 9) is a potent and selective proprotein convertase furin inhibitor with a Ki of 12.4 nM. Furin-IN-3 shows a Ki of 278 nM for PC7. Furin-IN-3 shows a significant antiviral effect on the Furin-dependent H7N7 influenza A virus strain SC35M. Furin-IN-3 can inhibit the cleavage and activation of the viral hemagglutinin (HA), prevent the fusion of the viral membrane with the host cell membrane, and thereby inhibit viral replication and proliferation. Furin-IN-3 can be used for the research of infection, such as influenza virus infection .
    Furin-IN-3
  • HY-183929
    Antiviral agent 87

    		Influenza Virus Infection
    Antiviral agent 87 is a potent antiviral agent with low cytotoxicity in host cells. Antiviral agent 87 stabilizes prefusion HA conformation, blocks viral membrane fusion and host cell entry, and inhibits entry and replication of diverse influenza A virus subtypes. Antiviral agent 87 can be used for the research of influenza A virus infection .
    Antiviral agent 87
  • HY-P991766
    Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57)

    		Flavivirus Infection
    Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57) reacts with the E2 protein of the Venezuelan equine encephalitis virus (VEEV). Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57) inhibits VEEV attachment to Vero cells, viral egress, viral fusion, and LDLRAD3-D1-Fc binding. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981) .
    Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57)
  • HY-180272
    TMV-IN-15

    		TMV Fungal Infection
    MV-IN-15 (compound 4AF) is a potent antiviral and antifungal agent. TMV-IN-15 suppresses viral particle assembly by binding to the TMV-CP, inducing prominent aggregation and structural fusion. TMV-IN-15 exhibits inhibitory activity against Physalospora piricola and Rhizoctonia cereal. TMV-IN-15 can be used for pesticides research .
    TMV-IN-15
  • HY-P992423
    NIAID RSVF2-5

    		RSV Infection
    NIAID RSVF2-5 is a human monoclonal antibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSV subgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection .
    NIAID RSVF2-5
  • HY-183185
    BZ-30

    		SARS-CoV Infection
    BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19 .
    BZ-30
  • HY-175829
    SARS-CoV-2-IN-119

    		SARS-CoV Infection
    SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor. SARS-CoV-2-IN-119 strongly inhibits Omicron entry with an EC50s of 1.95  and 1.08 μM for pOmicron (BA.2.86.1) and wild Omicron. SARS-CoV-2-IN-119 also has antiviral activities against wild SARS-CoV-2 and other variants, such as pseudotyped Delta SARS-CoV-2, pOmicron (BA.4) and (KP.3). SARS-CoV-2-IN-119 directly interferes with Omicron S2-mediated viral membrane fusion to block Omicron virus into host cells. SARS-CoV-2-IN-119 can be used for COVID-19 research .
    SARS-CoV-2-IN-119
  • HY-181785
    Influenza A virus-IN-18

    		Influenza Virus Infection
    Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor of Influenza A virus (IC50: 2.5 μM against PR8/H1N1; 6.42 μM against H3N2). Influenza A virus-IN-18 binds directly to the H1N1/PR8 HA protein with high affinity, with a KD of 0.25 μM. Influenza A virus-IN-18 is applicable to research related to Influenza A virus infection .
    Influenza A virus-IN-18
  • HY-P992155
    Arevirumab

    Arevirumab-3

    		 Arenavirus Infection
    Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever .
    Arevirumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: